Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab soravtansine + bevacizumab versus bevacizumab maintenance in FRα-high platinum-sensitive recurrent ovarian cancer
CTR20241552Phase 3Active
- Sponsor
- ImmunoGen
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mirvetuximab soravtansine, bevacizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by ImmunoGen. Started Sep 2024; status: active.
02
Drugs
mirvetuximab soravtansinebevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20241552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241552.